News

Emmes today announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary Advantage eClinical system. The ACTT-3 trial assessed the efficacy and safety of interferon beta-1a plus remdesivir compared to remdesivir alone in hospitalized adults with COVID-19.

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced a partnership with MedGenome aimed at accelerating breakthrough treatments, powered by human genomics, for rare disease patients.

Emmes – a full service, global clinical research organization (CRO) – is launching its new center, Orphan Reach™ as a unique ‘rare CRO’. The new rare disease center will incorporate Emmes’ world class reputation in public health research across the public sector and biopharmaceutical industry, with the expertise of Orphan Reach, a UK-based specialty CRO acquired by Emmes in May 2021.

Emmes and Veeva Systems (NYSE: VEEV) today announced that Emmes is standardizing on Veeva Development Cloud applications across functional areas to enable greater speed and compliance. The company will use applications in Vault Clinical, Vault Quality, and Vault Safety suites to establish a technology foundation for delivering clinical research and pharmacovigilance services to its global customers.

Emmes today announced that it launched a new study assessing the durability of response to COVID-19 vaccinations in patients with hematological malignancies who are undergoing cellular therapies, such as blood or marrow transplantation or CAR-T infusions. The study is part of an expanded portfolio of projects conducted under the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

Emmes today announced that it was selected as one of the best places to work in the greater Washington area. This is the fifth time that the company has been chosen as a top workplace by The Washington Post, whose rankings are based on the highest employee engagement ratings. The Post’s 2021 Top Workplaces list included a wide range of organizations, including government contractors, law and real estate firms, professional and business services firms, and technology companies.

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Orphan Reach, a company headquartered in the United Kingdom with offices in Ireland, Germany, India, Canada, and the U.S. Started nearly 20 years ago, Orphan Reach is a CRO dedicated to clinical research in rare diseases.

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Rhonda Henry has joined the company as President of Emmes BioPharma.

Christine Dingivan’s first job delivering newspapers in junior high school was “a terrible experience,” she said, requiring a 2 a.m. wake-up call and, at times, her dad when her bike proved inefficient in Long Island, New York. Her dream to become a professional athlete also didn’t pan out, causing her family to encourage a pursuit in academics instead.

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced its contribution to a study for the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) and a related article published in the New England Journal of Medicine. Emmes statisticians Gaurav Sharma, Ph.D., and Aimee Wahle were co-authors of the article, “Bupropion and Naltrexone in Methamphetamine Use Disorder.”

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced the company’s involvement in a recent article published in the New England Journal of Medicine. Emmes’ Carrie Brown and Dr. Steffanie Wilson were among the team of researchers who contributed to the article, “Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy.”

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced significant progress in its role as Data Coordinating Center for studies conducted under the Best Pharmaceuticals for Children Act (BPCA). Results from the Emmes-managed clinical trials, conducted through the BPCA Clinical Coordinating Center at Pediatric Trials Network, contributed directly to improved drug labeling for a range of products used in treating infants and children.